Phase 1 Parkinson's Clinical Trials
28 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 28 trials
Recruiting
Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
DementiaParkinson's Disease
National Institute of Mental Health (NIMH)184 enrolled1 locationNCT04396873
Recruiting
Phase 1Phase 2
rTMS to Improve Cognition in Parkinson's
Mild Cognitive ImpairmentParkinson's Disease
VA Office of Research and Development56 enrolled2 locationsNCT03836950
Recruiting
Phase 1
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
PARKINSON DISEASE (Disorder)Advanced Parkinson's Disease
Serina Therapeutics40 enrolled6 locationsNCT07422675
Recruiting
Phase 1
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
Parkinson DiseaseParkinson's Disease
Innopeutics Corporation6 enrolled1 locationNCT07371338
Recruiting
Phase 1
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
Healthy Volunteers (HV)Parkinson's Disease (PD)
Vertero Therapeutics84 enrolled1 locationNCT07310264
Recruiting
Phase 1Phase 2
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
Parkinson's Disease
Sumitomo Pharma America, Inc.25 enrolled2 locationsNCT06753331
Not Yet Recruiting
Phase 1
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered BT-409 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BT-409 in Adults with Parkinson’s disease.
Parkinson's Disease
Diagenta Au PTY LTD12 enrolled1 locationACTRN12626000206325
Not Yet Recruiting
Phase 1
A Phase 1, Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered BT-409 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of BT-409 in Healthy Volunteers.
Parkinson's Disease
Diagenta AU PTY LTD64 enrolled1 locationACTRN12626000191392
Recruiting
Phase 1
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
Parkinson's Disease
Prevail Therapeutics108 enrolled4 locationsNCT06565195
Recruiting
Phase 1
A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease
Parkinson's Disease (PD)
Fujita Health University24 enrolled1 locationNCT07170475
Recruiting
Phase 1
The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease
Parkinson's Disease
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.12 enrolled1 locationNCT07080775
Recruiting
Phase 1
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
Parkinson's Disease
Craig van Horne, MD, PhD24 enrolled1 locationNCT06683378
Completed
Phase 1
A clinical study to compare the safety and tolerability of two formulations of a new drug in Healthy Participants for Parkinson's disease.
Parkinson's Disease
Gain Therapeutics, Australia Pty Ltd (local Sponsor)24 enrolled1 locationACTRN12625000473460
Recruiting
Phase 1
An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous OV350 in Healthy Male and Female Participants
Parkinson's Disease
Ovid Therapeutics Australia Pty Ltd72 enrolled1 locationACTRN12625000428460
Recruiting
Phase 1
Home-based Transcranial Static Magnetic Field Stimulation (tSMS) of the Supplementary Motor Area in Parkinson's Disease
Parkinson's Disease
Fundación de investigación HM20 enrolled1 locationNCT06840678
Recruiting
Phase 1
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
PD - Parkinson's Disease
University of California, San Diego7 enrolled1 locationNCT06482268
Recruiting
Phase 1
A Randomised, Double-Blind, Placebo-Controlled, First-in-Human Study of Orally Administered ZE75-0267 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ZE75-0267 in Healthy Volunteers
Parkinson's Disease
Brenig Therapeutics AU Pty Ltd. (subsidiary of Brenig Therapeutics )64 enrolled1 locationACTRN12624001426572
Recruiting
Phase 1
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
Early-onset Parkinson's Disease
iRegene Therapeutics Co., Ltd.6 enrolled1 locationNCT06608355
Completed
Phase 1
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part B
Parkinson's Disease (PD)Chronic Myeloid Leukaemia (CML)
Enliven Therapeutics, Inc.15 enrolled1 locationACTRN12624000116527
Completed
Phase 1
A study to evaluate safety, tolerability and pharmacokinetics of ELVN-001 in Normal Healthy Participants- Part A
Parkinson's Disease (PD)Chronic Myeloid Leukaemia (CML)
Enliven Therapeutics, Inc.15 enrolled1 locationACTRN12624000115538